All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study

Authors
Category Primary study
JournalGastroenterology
Year 2015
This article has no abstract
Epistemonikos ID: 625a22b6eefb24c7c70f64328419f846deb580a3
First added on: Feb 07, 2025